Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 3Neoplasms 2Plasmacytoma 1Pathologic Complete Response 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Large Granular Lymphocytic 1Hepatic Insufficiency 1Hematologic Neoplasms 1Hematologic Diseases 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Dexamethasone 3daratumumab 2Lenalidomide 2pomalidomide 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1dexamethasone acetate 1dexamethasone 21-phosphate 1cc-486 1carfilzomib 1auricularum 1Specimen Handling 1Radiotherapy 1Immunotherapy, Adoptive 1Calcium Dobesilate 1Bortezomib 1Biopsy 12-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Plasmacytoma × cc-486 × 1 year × Clear all
NCT04174196 2025-12-02

A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
21 enrolled
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡